Tolerability and Pharmacokinetics of Lobeglitazone (CKD-501), a Peroxisome Proliferator-Activated Receptor-gamma Agonist: A Multiple-Dose, Double-Blind, Randomized Control Study in Healthy Male Korean Subjects.
Phase of Trial: Phase II
Latest Information Update: 31 Oct 2011
At a glance
- Drugs Lobeglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- 31 Oct 2011 Results published in the Clinical Therapeutics.
- 05 Nov 2010 New trial record.